603309.SH
Well Lead Medical Co., Ltd.
SSE · Healthcare · Medical - Instruments & Supplies · CN
CNY 11.30
−2.25%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.6B | 1.6B | 1.5B | 1.4B | 1.4B |
| Cost of Revenue | 900.4M | 901.4M | 837.2M | 750.9M | 774.5M |
| Gross Profit | 739.6M | 729.7M | 672.1M | 636.8M | 588.9M |
| Operating Expenses | |||||
| R&D Expense | 116.6M | 115.7M | 111.1M | 94.9M | 82.1M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 135.2M | 133.5M | 129.9M | 133.6M | 130.4M |
| Selling & Marketing Expense | 168.4M | 168.0M | 158.2M | 158.4M | 156.0M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 467.5M | 457.5M | 417.7M | 407.8M | 380.1M |
| Cost and Expenses | 1.4B | 1.4B | 1.3B | 1.2B | 1.2B |
| Operating Income (EBIT) | 131.8M | 130.5M | 265.5M | 238.8M | 206.7M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 131.7M | 130.3M | 263.0M | 237.3M | 205.7M |
| Income Tax Expense | 43.3M | 43.2M | 34.6M | 32.7M | 27.9M |
| Bottom Line | |||||
| Net Income | 77.3M | 76.3M | 219.4M | 192.5M | 166.6M |
| Earnings from Cont. Ops | 88.4M | 87.1M | 228.5M | 204.6M | 177.8M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 77.3M | 76.3M | 219.4M | 192.5M | 166.6M |
| Per Share | |||||
| Basic EPS | CN¥0.27 | CN¥0.26 | CN¥0.75 | CN¥0.66 | CN¥0.57 |
| Diluted EPS | CN¥0.27 | CN¥0.26 | CN¥0.75 | CN¥0.66 | CN¥0.57 |
| Revenue Per Share | CN¥5.75 | CN¥5.56 | CN¥5.16 | CN¥4.76 | CN¥4.67 |
| Shares | |||||
| Basic Shares Outstanding | 285.5M | 293.6M | 292.5M | 291.6M | 292.2M |
| Diluted Shares Outstanding | 285.5M | 293.6M | 292.5M | 291.6M | 292.2M |
| Profitability Metrics | |||||
| EBITDA | — | 216.1M | 336.4M | 306.3M | 265.6M |
| D&A | — | 85.7M | 70.9M | 67.5M | 58.9M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026